When digital photography killed the film industry, Kodak went bankrupt. Fujifilm did not. CEO Shigetaka Komori asked what the company actually knew how to do. The answer — advanced chemistry, precision coating, and nanotechnology — opened doors into cosmetics, pharmaceuticals, and materials science. The company that once sold camera film now makes everything from skincare to pharmaceuticals.
The strategic fork
90%+
Film Market Decline
Global photographic film demand collapsed by over 90% between 2000 and 2010
$21B
Fujifilm Revenue (2019)
Total consolidated revenue, driven by healthcare, materials, and imaging solutions
Bankruptcy
Kodak's Fate
Kodak filed Chapter 11 in January 2012; Fujifilm thrived through the same disruption
Fujifilm's Transformation: From Film to Frontier Science
2000
Peak Film
Global photographic film demand reaches its all-time peak. Fujifilm and Kodak are the dominant players. Digital camera sales are accelerating but have not yet reached mass adoption.
2003
Komori Takes Command
Shigetaka Komori becomes CEO of Fujifilm. He immediately begins auditing the company's technological capabilities and identifying adjacent markets where its chemistry expertise can create competitive advantages.
2006
VISION 75 Strategy Crystallizes
Fujifilm revises VISION 75, the medium-term plan it first announced in 2004, to pivot toward healthcare, materials, and document solutions. Massive R&D investments begin flowing into pharmaceutical research and LCD optical films.
2008
Toyama Chemical Acquisition
Fujifilm acquires a majority stake in Toyama Chemical Company, a Japanese pharmaceutical firm — signaling its serious commitment to the healthcare sector.
2012
Kodak Files for Bankruptcy
Eastman Kodak files for Chapter 11 bankruptcy protection. The company that invented the digital camera but refused to cannibalize its film business becomes the cautionary tale of the digital age.
2020
Pandemic Spotlight
Fujifilm's subsidiary Toyama Chemical gains global attention as its antiviral drug Avigan (favipiravir) is tested as a potential COVID-19 treatment.
The decisive moment in Fujifilm's transformation came not in a boardroom but in the company's research laboratories in Kanagawa, Japan. Shortly after becoming CEO in 2003, Shigetaka Komori ordered a comprehensive audit of Fujifilm's technological assets — not its products, but its underlying scientific capabilities. The audit identified core competencies ranging from collagen chemistry and nanotechnology to precision optical coatings and functional polymer design. Fujifilm's leadership then mapped each technology domain against potential commercial applications. Collagen and antioxidant chemistry pointed toward cosmetics. Chemical synthesis and molecular design pointed toward pharmaceuticals. Optical film coatings pointed toward flat-panel displays. Precision imaging pointed toward medical diagnostics. The result was a strategic blueprint that would guide billions of dollars in investment over the next decade. While Kodak's leadership was still debating how to slow the decline of film, Fujifilm had already identified its next five businesses.
Signal
- ●Digital camera resolution had reached 3+ megapixels — good enough for most consumers — and prices were falling rapidly
- ●Film processing labs were closing worldwide as consumers shifted to digital printing and online sharing
- ●Fujifilm's own technology audit revealed capabilities with applications far beyond photography
- ●LCD flat-panel display production was accelerating, requiring advanced optical films Fujifilm could produce
Noise
- ●Professional photographers will always prefer film for quality — the high-end market will sustain us
- ●Digital photography is a fad for consumers; serious imaging will stay analog
- ●Fujifilm should double down on film and ride out the transition period
- ●Diversification into unrelated fields like cosmetics will confuse the brand
- ●The Chinese and Indian markets are still growing for film — emerging markets will save us
Shigetaka Komori
CEO and Chairman, Fujifilm Holdings (2003-2021)
Capability-Based Thinking
Komori refused to define Fujifilm by its product (film) and instead defined it by its capabilities (advanced chemistry, nanotechnology, precision coating). This single reframing unlocked an entirely new strategic landscape and is the intellectual foundation of the entire transformation.
Speed and Decisiveness
Komori moved with extraordinary speed. Within three years of becoming CEO, he was restructuring the company around new growth areas. He understood that in a collapsing market, hesitation equals death.
Willingness to Invest Through the Storm
While film revenue was declining, Komori was investing billions in new businesses. This required enormous conviction and courage, because the payoffs from healthcare and materials investments wouldn't materialize for years.
Operational Ruthlessness
Komori did not sentimentalize the film business. He cut 5,000 manufacturing jobs, closed factories, and restructured the film division with cold efficiency — freeing resources for the new growth areas.
Cultural Resistance to 'Non-Core' Businesses
Fujifilm employees took pride in being a photography company. The idea of selling cosmetics and pharmaceuticals felt alien and even undignified to many long-tenured staff. Internal skepticism about the Astalift skincare line was particularly strong.
Massive Restructuring Costs
Komori had to cut 5,000 jobs and close film manufacturing facilities while simultaneously investing billions in new businesses. The short-term financial pain was severe, and the board faced pressure from investors who questioned whether the investments would ever pay off.
Pharmaceutical Industry Barriers
Entering the pharmaceutical business required navigating complex regulatory environments, building clinical trial capabilities, and competing against entrenched players like Pfizer and Roche. The Toyama Chemical acquisition was a major bet with uncertain returns.
The Kodak Comparison Trap
Analysts and media constantly compared Fujifilm to Kodak, reinforcing a narrative that both film companies were doomed. This created negative market sentiment that made it harder for Fujifilm to attract new talent and investor confidence for its non-film ventures.
Inside the War Room
The 5,000-Job Restructuring
In 2006, Komori announced the elimination of 5,000 positions, primarily in film manufacturing. Komori understood that sentimentality about the film workforce would doom the entire company. He invested heavily in retraining programs and redeployed as many employees as possible into the growing healthcare and materials divisions.
The Toyama Chemical Acquisition
Acquiring a majority stake in Toyama Chemical in 2008 was a major bet for Fujifilm. The pharmaceutical company brought drug development capabilities and a pipeline that included Avigan, an antiviral drug. A decade later, when Avigan became a candidate COVID-19 treatment, the acquisition looked prescient.
Immediate Aftermath
Fujifilm launched its Astalift cosmetics line in Japan in 2007
5,000 film manufacturing jobs were eliminated, freeing resources for growth investments
The Toyama Chemical acquisition gave Fujifilm a credible pharmaceutical platform
Revenue diversification began immediately, reducing dependence on the collapsing film market
Long-Term Ripple
By 2019, total revenue had grown to $21 billion
Fujifilm's optical films became essential components in LCD screens
Kodak filed for bankruptcy in 2012
“Fujifilm's transformation is a vivid example of capability-based strategy. While Kodak defined itself by its product and died with it, Komori defined Fujifilm by its underlying science and built an entirely new company on that foundation. The lesson is universal: when disruption threatens your product, the survival question is not 'How do we save what we sell?' but 'What do we know how to do that the world still needs?'”
Successful Strategic Transformation
The 'Capability Transfer' Pattern
Fujifilm's pivot exemplifies the most sophisticated form of corporate transformation: identifying deep capabilities hidden beneath a dying product and transferring them to growing markets. This is fundamentally different from a conventional diversification. Fujifilm didn't enter cosmetics because cosmetics were a growing market — it entered cosmetics because its collagen chemistry gave it a genuine competitive advantage there. The pattern requires brutal self-honesty about what you actually know (not what you sell) and the imagination to see where that knowledge creates value. Very few companies achieve this.
The decisive moment
In the year 2000, Fujifilm and Eastman Kodak stood as twin giants of the photographic film industry. Both companies had built global empires on the same core product: light-sensitive chemical film. Both faced the same existential threat: digital photography was rapidly making that product obsolete. Global demand for photographic film peaked around 2000 and then fell off a cliff. By 2010, the film market had shrunk by over 90%. What happened next is a stark divergence. Kodak filed for Chapter 11 bankruptcy in January 2012. Fujifilm, by contrast, was thriving.
The difference was Shigetaka Komori. Appointed CEO of Fujifilm in 2003, Komori had spent his career in the company and understood its capabilities at a molecular level — literally. While the business world saw Fujifilm as a film company, Komori saw it as an advanced chemistry company that happened to sell film. Photographic film manufacturing required mastery of collagen science, antioxidant chemistry, nanotechnology, precision optical coatings, and the manipulation of molecular structures at angstrom-level precision. These were not narrow skills — they were foundational capabilities that could be applied across dozens of industries. Komori's insight was simple but profound: Fujifilm's core competence was not film. It was the science beneath the film.
Komori launched a strategic plan called 'VISION 75', announced in 2004, revised in 2006 and named for the company's 75th anniversary in 2009. Fujifilm systematically built positions in markets where its chemistry expertise created genuine competitive advantages. In cosmetics, Fujifilm's knowledge of collagen and antioxidants — developed to prevent photos from fading — became the foundation of the Astalift skincare line. In pharmaceuticals, the company's expertise in chemical synthesis and molecular design led to partnerships and acquisitions, including the purchase of Toyama Chemical, whose antiviral drug Avigan would later gain global attention during the COVID-19 pandemic. In flat-panel displays, Fujifilm's optical film coatings became essential components in LCD screens. In medical imaging, the company built on its existing X-ray film business to become a major player in digital diagnostic systems.
The financial transformation was dramatic. In 2000, photographic products accounted for roughly 60% of Fujifilm's sales. By 2019, total revenue had grown to about $21 billion. Healthcare and materials solutions now drove the business, with operating profits far exceeding what the old film business had ever generated. Meanwhile, Kodak — which had invented the digital camera in 1975 but refused to cannibalize its film business — had been reduced to a shell of its former self after emerging from bankruptcy in 2013 as a small commercial printing company.
The Fujifilm story is not merely a tale of survival — it is a study in strategic reinvention. Komori understood something that eludes most executives facing disruption: the question is not 'How do we save our product?' but 'What capabilities do we have that the world still needs?' By redefining Fujifilm's identity around its deepest competencies rather than its most visible product, Komori turned an impending death sentence into a second life. The company that once competed with Kodak for shelf space at drugstores now sells pharmaceuticals and skincare products.
Apply the lessons
A framework for surviving industry disruption by identifying transferable capabilities and redirecting them to growing markets.
Audit capabilities, not products
Conduct a comprehensive inventory of your organization's deep technical and operational capabilities — the skills and knowledge that exist beneath your current products. What do you actually know how to do?
Map capabilities to growing markets
For each core capability, identify markets where that expertise creates genuine competitive advantage. Fujifilm's collagen chemistry mapped to cosmetics; its optical coatings mapped to LCD displays. The diversification must be capability-led, not opportunistic.
Invest aggressively while you still can
Use cash flow from the declining business to fund the pivot before the cash runs out. Fujifilm invested heavily while film revenue was still flowing. Kodak waited too long and had nothing left to invest.
Restructure without sentiment
Cut the declining business ruthlessly to free resources for the new one. Komori eliminated 5,000 jobs.
Frequently asked questions
How did Fujifilm survive while Kodak went bankrupt?+
What businesses did Fujifilm enter after film declined?+
What was Fujifilm's connection to COVID-19 treatments?+
What is the key lesson from the Fujifilm vs. Kodak story?+
It's 2000. You and Kodak both make photographic film. Digital is about to make it obsolete.
What do you do?
Kodak and the digital camera
The twin that answered the same question the other way.
How to Self-Disrupt Without Killing Your Cash Cow — Eating your own profitable product before a rival does is the right move more often than not. Doing it without a customer revolt is the hard part — and it's where most companies, Netflix included, blow themselves up.
How to Turn a Company Around Before It's Too Late — Every great turnaround answers two questions correctly: is the core business actually dying, and is there a credible new engine to replace it? Get those wrong and you either pivot away from a healthy business or cling to a dying one. Kodak and Fujifilm faced the identical shock — and answered differently.
More Strategic Forks
Other consequential decisions worth studying.
Starbucks Closes 8,000 Stores for Racial Bias Training
On April 12, 2018, a Starbucks manager in Philadelphia called police on two Black men who were waiting for a business meeting without ordering. The arrest went viral. Six weeks later, Howard Schultz closed all 8,000+ company-owned U.S. stores for an afternoon of racial bias training — 175,000 employees, an estimated $12 million in lost revenue, one message: this is not who we are. Was it a genuine strategic pivot in corporate responsibility, or theater at scale?
Current ForksThe Global South AI Adoption Fast Lane
While Europe builds regulatory frameworks and the US debates safety guardrails, India and Southeast Asia are pursuing aggressive AI deployment through fast lanes for innovation. Microsoft pledged in February 2024 to give 2 million people in India AI skills by 2025, and in January 2025 raised the goal to 10 million people by 2030. Abu Dhabi's Government Digital Strategy 2025–2027, announced in January 2025, aims to make it the world's first fully AI-native government by 2027. Organizations focused exclusively on Western markets may find themselves outpaced by competitors building capabilities in the world's fastest-growing regions.
Technology & InnovationApple Opens the App Store (2008)
Steve Jobs launched the iPhone in 2007 with a firm conviction: no third-party native apps. The phone was perfect as shipped, and web apps would handle everything else. Within months, developers were jailbreaking iPhones to install their own software. Jobs' reversal — opening the App Store in July 2008 — created one of the most valuable software marketplaces in the world and transformed Apple from a hardware company into a platform empire.
Crisis & RecoveryJohnson & Johnson's Tylenol Recall (1982)
When cyanide-laced Tylenol capsules killed seven people in Chicago in 1982, Johnson & Johnson faced an existential threat. CEO James Burke's decision to recall every bottle in America — despite reported FBI and FDA concern that a national recall could cause panic — cost $100 million but created the modern playbook for corporate crisis response. Within about a year, Tylenol had won back most of its lost market share.
Mergers & AcquisitionsHP Acquires Autonomy (2011)
When HP CEO Leo Apotheker paid $11.1 billion for Autonomy in 2011, he was trying to transform HP from a hardware manufacturer into a software powerhouse. Instead, the deal produced an $8.8 billion write-down, allegations of massive fraud, criminal charges, and a case study in due diligence failure that continues to haunt corporate boardrooms. A UK civil court found in 2022 that founder Mike Lynch had committed fraud; a U.S. criminal jury acquitted him in 2024.
Organizational & GovernanceGoldman Sachs Goes Public (1999)
When Goldman Sachs rang the opening bell at the NYSE on May 4, 1999, it ended a 130-year tradition of private partnership. The offering raised about $3.66 billion, while partners' own shares were largely locked up. The question that haunted Wall Street: could a culture built on shared risk and long-term thinking survive the quarterly earnings treadmill?
More from Stratrix
Test a decision, free
Set a live decision against the companies that made it before you.
AcquisitionsThe Distance TestDivestituresThe Divestiture TestDiversificationThe Diversification TestMake or buyThe Make-or-Buy TestAll Access
Every Casebook, three Strategy Packs a seat each year and the Analyst, for teams that face these decisions all year.
$1,999 a year · $499 a seatWhat is included →New analyses, by email
The defining moves in business, checked against the record, as they publish.
Sources & further reading
- Shigetaka Komori (2015). Innovating Out of Crisis: How Fujifilm Survived (and Thrived) As Its Core Business Was Vanishing. Stone Bridge Press.
- Giovanni Gavetti, Yaichi Aoshima and Mary Tripsas (2007). Fujifilm: A Second Foundation. Harvard Business School.
Cite this analysis
Stratrix. (2026). Fujifilm Pivots Beyond Film. Strategic Forks. Retrieved from https://www.stratrix.com/strategic-forks/fujifilm-pivot
From the fork to the next read.
Study the strategic fork, understand the decision, then follow the thread across the companies and lenses it connects to.